VANCOUVER, British Columbia, May 07, 2018 -- Silvercorp Metals Inc. ("Silvercorp” or the “Company”) (TSX:SVM) (NYSE American:SVM) announces that its financial and operating results for the fiscal year ended March 31, 2018 will be released on Thursday, May 24, 2018 after the market close.
About Silvercorp Metals Inc.
Silvercorp is a low-cost silver-producing Canadian mining company with multiple mines in China. The Company’s vision is to deliver shareholder value by focusing on the acquisition of under developed projects with resource potential and the ability to grow organically. For more information, please visit our website at www.silvercorpmetals.com.
Investor Contact
Lorne Waldman
Senior Vice President
Silvercorp Metals Inc.
Phone: (604) 669-9397
Toll Free 1(888) 224-1881
Email: [email protected]
Website: www.silvercorp.ca.


Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal
Barclays Downgrades Siemens Energy as Valuation Seen Near Peak
SK Hynix’s $28 Billion U.S. Share Sale Draws Massive Demand Amid AI Chip Boom
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow
Japan Regional Bank Stocks Drop After Zentoshin Bankruptcy Sparks Credit Risk Concerns
Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO
Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices
Lockheed Martin, Rheinmetall Plan First ATACMS Missile Production in Germany
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy
SpaceX Stock Draws Bullish Wall Street Coverage Ahead of Nasdaq-100 Inclusion
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI
Bernstein Names IAG, Ryanair as Top European Airline Stocks Ahead of Earnings
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 



